However, recent studies have suggested that the anti-tumor effect of anti-CD47 treatment is also dependent on T cell activation3 and loss of CD47-SIRPα interaction between red blood cells and DCs triggered activation of both T cells and DCs4. This evidence concerns the gene CD47 and neoplasm.